首页 > 最新文献

Revue neurologique最新文献

英文 中文
Epidemiology of optic disc edema in 2021/2022: Results from a cohort of 197 patients. 2021/2022 年视盘水肿的流行病学:197 例患者的研究结果。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-17 DOI: 10.1016/j.neurol.2024.09.010
R Attia, N Stolowy, R Fitoussi, K Mairot, T David

Objective: The aim of our study was to determine the etiologies of optic disc edema between 2021 and 2022.

Materials and methods: This was a multicentric study at the Timone and Nord university hospitals in Marseille. Patients were retrospectively followed in ophthalmology departments, with inclusion between January 2021 and December 2022. All patients presenting with newly diagnosed uni- or bilateral optic disc edema, both adults and children, were included. Their ophthalmological evaluation included a fundus examination and optical coherence tomography if feasible.

Results: In total, 197 patients were included. Intracranial hypertension (IH) was the most frequent etiology (37.06%). The primary causes of IH were idiopathic (27/73), intracranial tumors (21/73), and cerebral venous thrombosis (12/73). The second etiology of optic disc edema was retinal vein occlusion in 19.9% of cases (39/197). Edema reactive to uveitis was found in 13.2% of cases (26/197). Finally, inflammatory (17/197) and ischemic (30/197) optic neuropathies were identified.

Conclusion: This study updates the most frequent etiologies of optic disc edema in 2021 and 2022 to facilitate diagnostic hypotheses for de novo optic disc edema. It highlights the importance of a comprehensive and personalized evaluation in diagnosing optic disc edema, taking into account recent advances in imaging techniques and biomarkers.

研究目的我们的研究旨在确定 2021 年至 2022 年间视盘水肿的病因:这是在马赛的蒂莫内和诺德大学医院进行的一项多中心研究。眼科部门对患者进行了回顾性随访,纳入时间为 2021 年 1 月至 2022 年 12 月。所有新确诊的单侧或双侧视盘水肿患者(包括成人和儿童)均被纳入研究范围。眼科评估包括眼底检查和光学相干断层扫描(如可行):结果:共纳入 197 名患者。颅内高压(IH)是最常见的病因(37.06%)。IH的主要病因是特发性(27/73)、颅内肿瘤(21/73)和脑静脉血栓(12/73)。视盘水肿的第二个病因是视网膜静脉闭塞,占 19.9%(39/197)。葡萄膜炎反应性水肿占 13.2%(26/197)。最后,还发现了炎症性(17/197)和缺血性(30/197)视神经病变:本研究更新了 2021 年和 2022 年最常见的视盘水肿病因,有助于对新发视盘水肿提出诊断假设。它强调了结合成像技术和生物标志物的最新进展,在诊断视盘水肿时进行全面和个性化评估的重要性。
{"title":"Epidemiology of optic disc edema in 2021/2022: Results from a cohort of 197 patients.","authors":"R Attia, N Stolowy, R Fitoussi, K Mairot, T David","doi":"10.1016/j.neurol.2024.09.010","DOIUrl":"https://doi.org/10.1016/j.neurol.2024.09.010","url":null,"abstract":"<p><strong>Objective: </strong>The aim of our study was to determine the etiologies of optic disc edema between 2021 and 2022.</p><p><strong>Materials and methods: </strong>This was a multicentric study at the Timone and Nord university hospitals in Marseille. Patients were retrospectively followed in ophthalmology departments, with inclusion between January 2021 and December 2022. All patients presenting with newly diagnosed uni- or bilateral optic disc edema, both adults and children, were included. Their ophthalmological evaluation included a fundus examination and optical coherence tomography if feasible.</p><p><strong>Results: </strong>In total, 197 patients were included. Intracranial hypertension (IH) was the most frequent etiology (37.06%). The primary causes of IH were idiopathic (27/73), intracranial tumors (21/73), and cerebral venous thrombosis (12/73). The second etiology of optic disc edema was retinal vein occlusion in 19.9% of cases (39/197). Edema reactive to uveitis was found in 13.2% of cases (26/197). Finally, inflammatory (17/197) and ischemic (30/197) optic neuropathies were identified.</p><p><strong>Conclusion: </strong>This study updates the most frequent etiologies of optic disc edema in 2021 and 2022 to facilitate diagnostic hypotheses for de novo optic disc edema. It highlights the importance of a comprehensive and personalized evaluation in diagnosing optic disc edema, taking into account recent advances in imaging techniques and biomarkers.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
French validation of the sexual complaints screener (SCS) for patients with multiple sclerosis. 多发性硬化症患者性主诉筛选器(SCS)的法国验证。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-14 DOI: 10.1016/j.neurol.2024.09.009
S Bresch, H Joly, R Colamarino, I Bentellis, S Tur, S Fakir, C Burte, C Lebrun-Frenay

Background: Sexual dysfunctions are frequent in the general population and even more frequent in individuals with chronic neurological disorders like multiple sclerosis (MS). Several studies indicate that patients would like healthcare workers to address sexual problems. Indeed, such complaints are not currently sufficiently detected and treated. In clinical practice, a screening tool is lacking to help French-speaking patients and healthcare professionals address this issue.

Objective: The main aim of this study was to evaluate the reliability and validity of the French adaptation of the self-assessment Sexual Complaints Screener scale for Women (SCS-W) and Men (SCS-M).

Method: A prospective study was conducted among patients with MS in two centers. The SCS-W was adapted into French (QPS-F: questionnaire de plaintes sexuelles - Femmes) and compared to the reference questionnaire Female Sexual Function Index-19 (FSFI-19). The SCS-M was adapted into French (QPS-H: questionnaire de plaintes sexuelles - Hommes) and compared to the reference International Index of Erectile Function-15 (IIEF-15).

Results: Included were 101 women and 35 men with MS. Median age was 40.5 (range: 20-68) years. Based on the Cronbach alpha coefficient, the internal coherence of the QPS in French was 0.89 for women (QPS-F) and 0.71 for men (QPS-H), indicating high reliability. For QPS-F, the bivariate Pearson correlation coefficient indicated good convergence for desire and satisfaction, and average convergence for orgasm, pain, and arousal excitability. For QPS-H, the convergence was good for desire, pleasure, and ejaculation.

Conclusion: The French versions of the SCS-W/M scales, namely QPS-F and QPS-H, are reliable and validated tools compared with the reference questionnaires, FSFI and IIEF-15, respectively. The QPS-F/H are useful tools for brief, simple, and accurate screening and assessment of sexual complaints. They provide supportive information for clinicians who are less familiar with the clinical significance of sexual complaints and hence can be helpful to achieve more adapted care. These scales are adapted, but not specific, to MS. They could be used in other pathologies and the general population.

背景:性功能障碍在普通人群中很常见,在多发性硬化症(MS)等慢性神经系统疾病患者中更为常见。多项研究表明,患者希望医护人员能够解决性问题。事实上,目前对这类投诉的检测和治疗还不够充分。在临床实践中,缺乏一种筛查工具来帮助讲法语的患者和医护人员解决这一问题:本研究的主要目的是评估改编自法语的女性(SCS-W)和男性(SCS-M)性投诉筛查自评量表的可靠性和有效性:方法:在两个中心的多发性硬化症患者中开展了一项前瞻性研究。将 SCS-W 改编成法文(QPS-F:sexuelles questionnaire de plaintes sexuelles - Femmes),并与参考问卷 "女性性功能指数-19"(FSFI-19)进行比较。SCS-M 被改编成法文(QPS-H:sexuelles questionnaire de plaintes sexuelles - Hommes),并与参考的国际勃起功能指数-15(IIEF-15)进行比较:结果:共纳入 101 名女性和 35 名男性多发性硬化症患者。中位年龄为 40.5 岁(范围:20-68 岁)。根据克朗巴赫α系数,法语 QPS(QPS-F)的内部一致性为 0.89,而法语 QPS(QPS-H)的内部一致性为 0.71,这表明 QPS 具有很高的可靠性。对于 QPS-F,双变量皮尔逊相关系数表明,欲望和满意度的趋同性较好,性高潮、疼痛和唤醒兴奋性的趋同性一般。对于 QPS-H,欲望、快感和射精的趋同性较好:结论:与参考问卷 FSFI 和 IIEF-15 相比,法文版 SCS-W/M 量表,即 QPS-F 和 QPS-H 是可靠且经过验证的工具。QPS-F/H 是简短、简单、准确筛查和评估性主诉的有用工具。它们为不太了解性主诉临床意义的临床医生提供了辅助信息,因此有助于实现更适合的护理。这些量表适用于多发性硬化症,但不具有特异性。它们可用于其他病症和普通人群。
{"title":"French validation of the sexual complaints screener (SCS) for patients with multiple sclerosis.","authors":"S Bresch, H Joly, R Colamarino, I Bentellis, S Tur, S Fakir, C Burte, C Lebrun-Frenay","doi":"10.1016/j.neurol.2024.09.009","DOIUrl":"https://doi.org/10.1016/j.neurol.2024.09.009","url":null,"abstract":"<p><strong>Background: </strong>Sexual dysfunctions are frequent in the general population and even more frequent in individuals with chronic neurological disorders like multiple sclerosis (MS). Several studies indicate that patients would like healthcare workers to address sexual problems. Indeed, such complaints are not currently sufficiently detected and treated. In clinical practice, a screening tool is lacking to help French-speaking patients and healthcare professionals address this issue.</p><p><strong>Objective: </strong>The main aim of this study was to evaluate the reliability and validity of the French adaptation of the self-assessment Sexual Complaints Screener scale for Women (SCS-W) and Men (SCS-M).</p><p><strong>Method: </strong>A prospective study was conducted among patients with MS in two centers. The SCS-W was adapted into French (QPS-F: questionnaire de plaintes sexuelles - Femmes) and compared to the reference questionnaire Female Sexual Function Index-19 (FSFI-19). The SCS-M was adapted into French (QPS-H: questionnaire de plaintes sexuelles - Hommes) and compared to the reference International Index of Erectile Function-15 (IIEF-15).</p><p><strong>Results: </strong>Included were 101 women and 35 men with MS. Median age was 40.5 (range: 20-68) years. Based on the Cronbach alpha coefficient, the internal coherence of the QPS in French was 0.89 for women (QPS-F) and 0.71 for men (QPS-H), indicating high reliability. For QPS-F, the bivariate Pearson correlation coefficient indicated good convergence for desire and satisfaction, and average convergence for orgasm, pain, and arousal excitability. For QPS-H, the convergence was good for desire, pleasure, and ejaculation.</p><p><strong>Conclusion: </strong>The French versions of the SCS-W/M scales, namely QPS-F and QPS-H, are reliable and validated tools compared with the reference questionnaires, FSFI and IIEF-15, respectively. The QPS-F/H are useful tools for brief, simple, and accurate screening and assessment of sexual complaints. They provide supportive information for clinicians who are less familiar with the clinical significance of sexual complaints and hence can be helpful to achieve more adapted care. These scales are adapted, but not specific, to MS. They could be used in other pathologies and the general population.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Migraine treatment: Position paper of the French Headache Society. 偏头痛治疗:法国头痛协会立场文件。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-14 DOI: 10.1016/j.neurol.2024.09.008
X Moisset, G Demarquay, S de Gaalon, C Roos, A Donnet, P Giraud, E Guégan-Massardier, C Lucas, J Mawet, D Valade, V Corand, C Gollion, N Moreau, L Grangeon, M Lantéri-Minet, A Ducros

The French migraine management recommendations were published in 2021. However, in the last three years, new data have come to light and new drugs have been approved (eptinezumab, rimegepant and atogepant) by the European Medicines Agency that require us to take a position on their use and to update certain elements of the recommendations. The first important message concerns the position of the French Headache Society on the use of preventive treatments (monoclonal antibodies and gepants) targeting the calcitonin gene-related peptide (CGRP) pathway. In terms of efficacy and safety, and as suggested by other national headache societies, these treatments can be offered as first-line treatment, although the scope defined by the French national health authority for possible reimbursement is limited to patients with severe migraine, at least eight headache days per month and for whom two previous preventive treatments have failed. Another important change concerns the position of topiramate as a preventive treatment for migraine in women of childbearing age. This treatment has been proposed as a first-line treatment for chronic migraine. However, recent pharmacovigilance data have highlighted a potential adverse effect on neurodevelopment in children exposed in utero. As a result, this treatment is formally contraindicated during pregnancy and must be used with extreme caution in women of childbearing age (effective contraception, no therapeutic alternative available and annual follow-up as with valproate). It can therefore no longer be offered as first-line treatment for women of childbearing age.

法国偏头痛管理建议于 2021 年发布。然而,在过去三年中,新的数据不断涌现,欧洲药品管理局也批准了新的药物(eptinezumab、rimgepant和atogepant),这就要求我们对这些药物的使用采取立场,并更新建议中的某些内容。第一个重要信息涉及法国头痛协会对使用针对降钙素基因相关肽(CGRP)通路的预防性治疗(单克隆抗体和gepants)的立场。就疗效和安全性而言,正如其他国家的头痛学会所建议的那样,这些疗法可作为一线治疗手段,但法国国家卫生当局规定的可报销范围仅限于严重偏头痛患者、每月头痛天数至少8天且之前两种预防性疗法均无效的患者。另一个重要变化涉及托吡酯作为育龄妇女偏头痛预防治疗药物的地位。该疗法已被建议作为慢性偏头痛的一线治疗方法。然而,最近的药物警戒数据显示,该药物可能会对子宫内接触该药物的儿童的神经发育产生不良影响。因此,该疗法被正式列为妊娠期禁忌症,育龄妇女在使用该疗法时必须格外谨慎(采取有效的避孕措施,没有其他治疗方法可供选择,并与丙戊酸钠一样每年进行随访)。因此,不能再将其作为育龄妇女的一线治疗药物。
{"title":"Migraine treatment: Position paper of the French Headache Society.","authors":"X Moisset, G Demarquay, S de Gaalon, C Roos, A Donnet, P Giraud, E Guégan-Massardier, C Lucas, J Mawet, D Valade, V Corand, C Gollion, N Moreau, L Grangeon, M Lantéri-Minet, A Ducros","doi":"10.1016/j.neurol.2024.09.008","DOIUrl":"https://doi.org/10.1016/j.neurol.2024.09.008","url":null,"abstract":"<p><p>The French migraine management recommendations were published in 2021. However, in the last three years, new data have come to light and new drugs have been approved (eptinezumab, rimegepant and atogepant) by the European Medicines Agency that require us to take a position on their use and to update certain elements of the recommendations. The first important message concerns the position of the French Headache Society on the use of preventive treatments (monoclonal antibodies and gepants) targeting the calcitonin gene-related peptide (CGRP) pathway. In terms of efficacy and safety, and as suggested by other national headache societies, these treatments can be offered as first-line treatment, although the scope defined by the French national health authority for possible reimbursement is limited to patients with severe migraine, at least eight headache days per month and for whom two previous preventive treatments have failed. Another important change concerns the position of topiramate as a preventive treatment for migraine in women of childbearing age. This treatment has been proposed as a first-line treatment for chronic migraine. However, recent pharmacovigilance data have highlighted a potential adverse effect on neurodevelopment in children exposed in utero. As a result, this treatment is formally contraindicated during pregnancy and must be used with extreme caution in women of childbearing age (effective contraception, no therapeutic alternative available and annual follow-up as with valproate). It can therefore no longer be offered as first-line treatment for women of childbearing age.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital myasthenic syndromes by Epsilon subunit mutations: Phenotypic profiles of 17 Algerian families. 由 Epsilon 亚基突变引起的先天性肌无力综合征:17 个阿尔及利亚家庭的表型特征。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-07 DOI: 10.1016/j.neurol.2024.09.007
M I Kediha, M Tazir, D Sternberg, B Eymard, L Ali Pacha

Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of rare genetic disorders. The acetyl choline receptor contains five subunits, with a predominance of mutations affecting the epsilon subunit gene called cholinergic receptor nicotinic epsilon (CHRNE) gene.

Objective: To study the clinical phenotype of 17 families with CHRNE gene mutations.

Methods: We report a series of 17 families with 22 affected patients carrying different mutations encoding CHRNE proteins.

Results: We studied their clinical and biological phenotypes, as well as their evolutionary profile and their response to the different therapies proposed. A phenotypic comparison was made between the families carrying the founding Maghrebian mutation and the other mutations found in this series.

Conclusion: The CHRNE gene mutations are the most frequent ones in CMS. The phenotypes reported in this study are heterogeneous, and can depend on the causative mutation.

背景:先天性肌无力综合征(CMS)是一组异质性的罕见遗传疾病。乙酰胆碱受体包含五个亚基,其中epsilon亚基基因(即胆碱能受体烟碱epsilon(CHRNE)基因)的突变占绝大多数:研究17个CHRNE基因突变家族的临床表型:方法:我们报告了一系列 17 个家族的 22 位患者,他们携带不同的 CHRNE 蛋白编码突变:结果:我们研究了这些患者的临床和生物学表型,以及他们的进化特征和对不同疗法的反应。我们对携带马格里布基因突变的家族与该系列中发现的其他基因突变家族进行了表型比较:结论:CHRNE 基因突变是 CMS 中最常见的突变。结论:CHRNE 基因突变是 CMS 中最常见的突变。本研究中报告的表型具有异质性,可能取决于致病突变。
{"title":"Congenital myasthenic syndromes by Epsilon subunit mutations: Phenotypic profiles of 17 Algerian families.","authors":"M I Kediha, M Tazir, D Sternberg, B Eymard, L Ali Pacha","doi":"10.1016/j.neurol.2024.09.007","DOIUrl":"https://doi.org/10.1016/j.neurol.2024.09.007","url":null,"abstract":"<p><strong>Background: </strong>Congenital myasthenic syndromes (CMS) are a heterogeneous group of rare genetic disorders. The acetyl choline receptor contains five subunits, with a predominance of mutations affecting the epsilon subunit gene called cholinergic receptor nicotinic epsilon (CHRNE) gene.</p><p><strong>Objective: </strong>To study the clinical phenotype of 17 families with CHRNE gene mutations.</p><p><strong>Methods: </strong>We report a series of 17 families with 22 affected patients carrying different mutations encoding CHRNE proteins.</p><p><strong>Results: </strong>We studied their clinical and biological phenotypes, as well as their evolutionary profile and their response to the different therapies proposed. A phenotypic comparison was made between the families carrying the founding Maghrebian mutation and the other mutations found in this series.</p><p><strong>Conclusion: </strong>The CHRNE gene mutations are the most frequent ones in CMS. The phenotypes reported in this study are heterogeneous, and can depend on the causative mutation.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The “zebra sign” after a lumbar puncture 腰椎穿刺后的 "斑马征"。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.03.010
{"title":"The “zebra sign” after a lumbar puncture","authors":"","doi":"10.1016/j.neurol.2024.03.010","DOIUrl":"10.1016/j.neurol.2024.03.010","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 831-833"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mindfulness in Parkinson's disease: A French national survey and a pilot intervention feasibility trial using the MBSR program (M-Park) 帕金森病的正念疗法:法国全国调查和使用 MBSR 计划(M-Park)的试点干预可行性试验。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.03.013
<div><h3>Background</h3><div><span>Non-pharmacological complementary interventions, particularly mind-body practices, are of growing importance in the management of Parkinson's disease (PD). Among these, </span>mindfulness<span><span> meditation seems particularly effective, especially on anxiety and depression symptoms. However, current knowledge on mindfulness standardized programs in PD is still limited, particularly in France. Aiming at improving this knowledge we designed the M-PARK study in two phases. Phase 1 consisted in a French national survey to explore expectations, needs and initiatives for </span>mindfulness meditation<span> for PD patients. Phase 2 was a clinical trial<span> with objectives to assess feasibility, acceptability and effects of a mindfulness (MBSR) program proposed to PD patients.</span></span></span></div></div><div><h3>Methods</h3><div><span>In phase 1, online questionnaires were addressed to members of a French PD patient's association (France Parkinson) and French MBSR<span> qualified instructors. In Phase 2, a clinical trial<span> involving 30 PD patients consisted of a standard MBSR program with two additional evaluation visits one month before and after the program. Data collection included a global clinical evaluation, assessment of depression and anxiety symptoms, sleep, pain and </span></span></span>quality of life<span> and a face-to-face interview for qualitative assessment of the acceptability and lived experience during the program. Three MBSR programs were proposed to three groups of ten patients: two were online due to the pandemic situation, one proposed to patients with no or minor fluctuations (group 1) and one for patients with slight to moderate fluctuations (group 2), and the last one face-to-face for patients with no or minor fluctuations (group 3).</span></div></div><div><h3>Results</h3><div>French survey: 209 responses were collected for the questionnaire sent to the members of the association France Parkinson; and 68 for the questionnaire sent to the instructors. Two-thirds of patients surveyed had heard of mindfulness meditation (66%), but were unaware of what this approach really consisted and how it could really help them. Few instructors (29%) had had to deal with patients with PD in their current practice. Yet 90% of patients surveyed indicated they were in favor of introducing this type of approach into their care.</div></div><div><h3>Clinical trial</h3><div><span>The results indicated that the program is feasible and acceptable both online and face-to-face for patients with PD. Among the 30 patients enrolled, 25 completed the program. No unwanted effects related to mindfulness meditation practice were observed. The results showed a statistically significant reduction in anxiety symptoms, depressive symptoms, and improvement in quality of life. Furthermore, no statistically significant change was measured for pain or sleep quality. There was no striking difference in results observed be
背景:在帕金森病(PD)的治疗过程中,非药物辅助干预措施,尤其是身心疗法的重要性与日俱增。其中,正念冥想似乎特别有效,尤其是对焦虑和抑郁症状。然而,目前有关帕金森病正念冥想标准化项目的知识仍然有限,尤其是在法国。为了增进这方面的知识,我们分两个阶段设计了 M-PARK 研究。第一阶段包括一项法国全国性调查,目的是了解帕金森病患者对正念冥想的期望、需求和举措。第二阶段为临床试验,目的是评估向帕金森病患者推荐的正念冥想(MBSR)计划的可行性、可接受性和效果:在第一阶段,向法国帕金森病患者协会(France Parkinson)成员和法国 MBSR 合格指导员发放了在线调查问卷。在第二阶段,30 名帕金森病患者参与了一项临床试验,其中包括一项标准的 MBSR 课程,以及课程前后一个月的两次额外评估访问。数据收集包括全面临床评估、抑郁和焦虑症状评估、睡眠评估、疼痛评估和生活质量评估,以及面对面访谈,以对项目的可接受性和生活体验进行定性评估。我们向三组共 10 名患者推荐了三个 MBSR 项目:其中两个项目因大流行而在线进行,一个项目推荐给无波动或轻微波动的患者(第 1 组),一个项目推荐给轻微至中度波动的患者(第 2 组),最后一个项目推荐给无波动或轻微波动的患者(第 3 组):法国调查:向法国帕金森协会会员发出的调查问卷共收到 209 份答复;向讲师发出的调查问卷共收到 68 份答复。三分之二的受访患者听说过正念冥想(66%),但并不知道这种方法的真正含义以及如何真正帮助他们。很少有指导者(29%)在其目前的实践中与帕金森病患者打过交道。然而,90% 的受访患者表示,他们赞成在护理中引入这种方法:临床试验:结果表明,无论是在线还是面对面,该计划对帕金森病患者来说都是可行和可接受的。在注册的 30 名患者中,有 25 人完成了该项目。没有观察到与正念冥想练习相关的不良反应。结果显示,焦虑症状、抑郁症状和生活质量的改善在统计学上有显著降低。此外,疼痛或睡眠质量方面的变化在统计学上并不明显。患者组之间的结果没有明显差异。在定性分析中,强调的主要主题与以下方面有关(i) 计划期间的生活体验;(ii) 日常生活的变化;(iii) 与疾病相关的变化。绝大多数完成计划的患者(24/25)认为他们的参与是积极或非常积极的。他们表示,在实施新的行为策略方面,尤其是在自我护理、接受和消除对疾病的认同方面,他们更好地管理了压力和情绪,也有了更大的自主权:结论:尽管人们对正念疗法抱有很高的期望,但帕金森氏症患者对现有的正念疗法项目知之甚少。然而,这项研究表明,无论是在线还是面对面提供的这些项目都特别有益,尤其是对焦虑和抑郁症状,至少在疾病的轻中度阶段是如此。
{"title":"Mindfulness in Parkinson's disease: A French national survey and a pilot intervention feasibility trial using the MBSR program (M-Park)","authors":"","doi":"10.1016/j.neurol.2024.03.013","DOIUrl":"10.1016/j.neurol.2024.03.013","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Non-pharmacological complementary interventions, particularly mind-body practices, are of growing importance in the management of Parkinson's disease (PD). Among these, &lt;/span&gt;mindfulness&lt;span&gt;&lt;span&gt; meditation seems particularly effective, especially on anxiety and depression symptoms. However, current knowledge on mindfulness standardized programs in PD is still limited, particularly in France. Aiming at improving this knowledge we designed the M-PARK study in two phases. Phase 1 consisted in a French national survey to explore expectations, needs and initiatives for &lt;/span&gt;mindfulness meditation&lt;span&gt; for PD patients. Phase 2 was a clinical trial&lt;span&gt; with objectives to assess feasibility, acceptability and effects of a mindfulness (MBSR) program proposed to PD patients.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;span&gt;In phase 1, online questionnaires were addressed to members of a French PD patient's association (France Parkinson) and French MBSR&lt;span&gt; qualified instructors. In Phase 2, a clinical trial&lt;span&gt; involving 30 PD patients consisted of a standard MBSR program with two additional evaluation visits one month before and after the program. Data collection included a global clinical evaluation, assessment of depression and anxiety symptoms, sleep, pain and &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;quality of life&lt;span&gt; and a face-to-face interview for qualitative assessment of the acceptability and lived experience during the program. Three MBSR programs were proposed to three groups of ten patients: two were online due to the pandemic situation, one proposed to patients with no or minor fluctuations (group 1) and one for patients with slight to moderate fluctuations (group 2), and the last one face-to-face for patients with no or minor fluctuations (group 3).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;French survey: 209 responses were collected for the questionnaire sent to the members of the association France Parkinson; and 68 for the questionnaire sent to the instructors. Two-thirds of patients surveyed had heard of mindfulness meditation (66%), but were unaware of what this approach really consisted and how it could really help them. Few instructors (29%) had had to deal with patients with PD in their current practice. Yet 90% of patients surveyed indicated they were in favor of introducing this type of approach into their care.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical trial&lt;/h3&gt;&lt;div&gt;&lt;span&gt;The results indicated that the program is feasible and acceptable both online and face-to-face for patients with PD. Among the 30 patients enrolled, 25 completed the program. No unwanted effects related to mindfulness meditation practice were observed. The results showed a statistically significant reduction in anxiety symptoms, depressive symptoms, and improvement in quality of life. Furthermore, no statistically significant change was measured for pain or sleep quality. There was no striking difference in results observed be","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 777-790"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140945982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herpes simplex virus-2 meningo-encephalitis hiding a criminal case of fatal methylmercury poisoning 隐藏着致命甲基汞中毒刑事案件的单纯疱疹病毒-2脑膜脑炎。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.05.004
{"title":"Herpes simplex virus-2 meningo-encephalitis hiding a criminal case of fatal methylmercury poisoning","authors":"","doi":"10.1016/j.neurol.2024.05.004","DOIUrl":"10.1016/j.neurol.2024.05.004","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 833-835"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discriminating factors in access to video-EEG for epilepsy surgery in a French tertiary epilepsy center 法国一家三级癫痫中心在癫痫手术中使用视频脑电图的鉴别因素。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.04.003
Equitable access to care and management is a priority for patients with epilepsy and may vary depending on each country's healthcare system. As this issue has not been specifically addressed in France, we conducted a retrospective study to identify discriminating factors in access to surgery at a French tertiary epilepsy center. Initially, we examined factors previously identified in other countries as influential in surgery access, including age at diagnosis, affected side, gender, years of education, socio-professional categories, and density of general practitioners in the residential area, in 293 consecutive French-native patients with refractory medial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS). Subsequently, we conducted a case-control study comparing patients born in France with 22 patients born abroad to specifically explore migratory status. The analysis revealed that the only three factors statistically influencing the delay between the onset of epilepsy and entry into video-EEG were early age at onset (associated with a longer delay), pensioner status (associated with a longer delay), and student status (associated with a shorter delay). Migratory status, gender, and socio-economic level (indirectly reflected by the level of education and socio-professional category) were not found to be discriminatory factors in access to video-EEG. Discrepancies between our study and foreign studies may be attributed to differences in healthcare systems and medical coverage among countries. Efforts in France to improve access to surgery should focus on enhancing communication among practitioners to promptly refer any MTLE-HS patient to an epilepsy surgery center, regardless of their age.
公平地获得护理和管理是癫痫患者的首要任务,而每个国家的医疗体系可能会有所不同。由于这一问题在法国尚未得到专门解决,因此我们进行了一项回顾性研究,以确定在法国一家三级癫痫中心接受手术的歧视性因素。首先,我们对 293 名连续就诊的法国本土难治性颞叶内侧癫痫和海马硬化症(MTLE-HS)患者进行了检查,这些因素包括诊断时的年龄、患侧、性别、受教育年限、社会职业类别以及居住区全科医生的密度。随后,我们进行了一项病例对照研究,将出生在法国的患者与 22 名出生在国外的患者进行了比较,以具体探讨移民状况。分析结果显示,在统计学上影响癫痫发病与视频脑电图检查之间延迟时间的因素只有三个,即发病年龄早(与延迟时间较长有关)、领取养老金者身份(与延迟时间较长有关)和学生身份(与延迟时间较短有关)。移民身份、性别和社会经济水平(通过教育水平和社会职业类别间接反映)并未成为影响患者接受视频脑电图检查的歧视性因素。我们的研究与国外研究之间的差异可能归因于各国医疗系统和医疗覆盖范围的不同。法国在提高手术可及性方面的努力应侧重于加强从业人员之间的沟通,以便及时将任何 MTLE-HS 患者转诊至癫痫手术中心,无论其年龄大小。
{"title":"Discriminating factors in access to video-EEG for epilepsy surgery in a French tertiary epilepsy center","authors":"","doi":"10.1016/j.neurol.2024.04.003","DOIUrl":"10.1016/j.neurol.2024.04.003","url":null,"abstract":"<div><div><span>Equitable access to care and management is a priority for patients with epilepsy and may vary depending on each country's healthcare system. As this issue has not been specifically addressed in France, we conducted a retrospective study to identify discriminating factors in access to surgery at a French tertiary epilepsy center. Initially, we examined factors previously identified in other countries as influential in surgery access, including age at diagnosis, affected side, gender, years of education, socio-professional categories, and density of general practitioners in the residential area, in 293 consecutive French-native patients with refractory medial temporal lobe epilepsy and </span>hippocampal sclerosis<span> (MTLE-HS). Subsequently, we conducted a case-control study comparing patients born in France with 22 patients born abroad to specifically explore migratory status. The analysis revealed that the only three factors statistically influencing the delay between the onset of epilepsy and entry into video-EEG were early age at onset (associated with a longer delay), pensioner status (associated with a longer delay), and student status (associated with a shorter delay). Migratory status, gender, and socio-economic level (indirectly reflected by the level of education and socio-professional category) were not found to be discriminatory factors in access to video-EEG. Discrepancies between our study and foreign studies may be attributed to differences in healthcare systems and medical coverage among countries. Efforts in France to improve access to surgery should focus on enhancing communication among practitioners to promptly refer any MTLE-HS patient to an epilepsy surgery center, regardless of their age.</span></div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 770-776"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Marian apparitions: A multidisciplinary approach. The case of Île Bouchard 玛利亚显灵:多学科方法。布沙尔岛案例。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.04.008
Discussing Marian apparitions in the light of current knowledge in neuroscience is a challenge: the testimonies are often old and indirect, and the “visionaries” could not be questioned or even examined according to current neurological or psychiatric standards. In doing so, we are not unaware of the heterogeneity of seers and the facts they reported: there is not necessarily a single hypothesis. It is the appearances of Île Bouchard that will be discussed here. Our interpretation calls on two non-exclusive “mechanisms”: on the one hand, mental imagery, which we know can be unconscious and is modulated or generated by frontal “top-down” mechanisms; on the other hand, the sociological consideration of events, using the concept of enchantment.
根据当前的神经科学知识来讨论圣母显灵是一项挑战:这些证词往往是陈旧而间接的,"显灵者 "无法受到质疑,甚至无法根据当前的神经学或精神病学标准进行检查。在此过程中,我们并非没有意识到先知及其所报告事实的异质性:不一定存在单一的假说。这里要讨论的是布沙尔岛的表象。我们的解释需要两种非排他性的 "机制":一方面是心理意象,我们知道这种意象可能是无意识的,并由前额 "自上而下 "的机制调节或产生;另一方面是对事件的社会学思考,使用 "着魔 "的概念。
{"title":"Marian apparitions: A multidisciplinary approach. The case of Île Bouchard","authors":"","doi":"10.1016/j.neurol.2024.04.008","DOIUrl":"10.1016/j.neurol.2024.04.008","url":null,"abstract":"<div><div>Discussing Marian apparitions in the light of current knowledge in neuroscience is a challenge: the testimonies are often old and indirect, and the “visionaries” could not be questioned or even examined according to current neurological or psychiatric standards. In doing so, we are not unaware of the heterogeneity of seers and the facts they reported: there is not necessarily a single hypothesis. It is the appearances of Île Bouchard that will be discussed here. Our interpretation calls on two non-exclusive “mechanisms”: on the one hand, mental imagery, which we know can be unconscious and is modulated or generated by frontal “top-down” mechanisms; on the other hand, the sociological consideration of events, using the concept of enchantment.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 828-830"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Model-based cueing-as-needed for walking in Parkinson's disease: A randomized cross-over study 基于模型的帕金森病患者行走提示:随机交叉研究
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.neurol.2024.05.003

Background

Correcting of the lack of regularity in steps is a key component of gait rehabilitation in Parkinson's disease. We proposed to introduce adaptive spatial auditory cueing (ASAC) based on verbal instruction “lengthen the step” automatically delivered when the stride length decreased below a predetermined threshold.

Objectives

The present study compared the effect of usual rhythmic auditory cueing versus ASAC used during a walking training in Parkinson's disease.

Methods

Fifteen patients with Parkinson's disease performed both interventions in randomized order, one week apart: a 20-minute walking training with rhythmic auditory cueing, in form of a metronome adjusted on 110% of the patient's own cadence, or ASAC delivered when the stride length is less than 110% of the patient's own stride length. Assessment criteria were walking distance covered during the intervention, speed, step length, cadence, coefficients of variation of step length and step duration, and indexes of spatial and temporal asymmetry during a walking test before and just after the intervention.

Results

The walking distance is higher with ASAC compared with rhythmic auditory cueing (rhythmic auditory cueing, 905 (203) m, mean (standard deviation); ASAC, 1043 (212) m; P = 0.002). Between-intervention comparison showed some similar effects on walking after the intervention including free speed and step length increases (P < 0.05).

Conclusion

The distance covered during 20-minute walking with ASAC increases by 15% compared to the use of classical rhythmic auditory cueing, while the immediate therapeutic effects show similar spatial-temporal benefits on short-distance walking. Auditory biofeedback cueing promoting the increase in step length might improve gait relearning in Parkinson's disease.
背景:纠正步伐缺乏规律性是帕金森病步态康复的关键组成部分。我们建议引入自适应空间听觉提示(ASAC),当步长下降到预定阈值以下时,自动发出 "延长步长 "的口头指令:本研究比较了帕金森病患者在步行训练中使用普通节奏性听觉提示与 ASAC 的效果:15名帕金森病患者按照随机顺序进行了两种干预,时间间隔为一周:20分钟的步行训练,采用节拍器的形式进行有节奏的听觉提示,节拍器调整为患者自身步速的110%,或在步长小于患者自身步长的110%时进行ASAC。评估标准包括干预期间的步行距离、速度、步长、步频、步长和步长变异系数,以及干预前后步行测试中的空间和时间不对称指数:结果:与有节奏的听觉提示相比,有节奏的听觉提示的步行距离更长(有节奏的听觉提示,905(203)米,平均值(标准差);有节奏的听觉提示,1043(212)米;P=0.002)。干预之间的比较显示,干预后的步行效果相似,包括自由速度和步长的增加(PC 结论:在 20 分钟的步行过程中,听觉提示的步行距离增加了 10%:与使用经典节奏性听觉提示相比,使用 ASAC 进行 20 分钟步行的距离增加了 15%,而即时治疗效果则显示出对短距离步行具有类似的时空益处。促进步长增加的听觉生物反馈提示可改善帕金森病患者的步态再学习能力。
{"title":"Model-based cueing-as-needed for walking in Parkinson's disease: A randomized cross-over study","authors":"","doi":"10.1016/j.neurol.2024.05.003","DOIUrl":"10.1016/j.neurol.2024.05.003","url":null,"abstract":"<div><h3>Background</h3><div>Correcting of the lack of regularity in steps is a key component of gait rehabilitation in Parkinson's disease<span>. We proposed to introduce adaptive spatial auditory cueing (ASAC) based on verbal instruction “lengthen the step” automatically delivered when the stride length decreased below a predetermined threshold.</span></div></div><div><h3>Objectives</h3><div>The present study compared the effect of usual rhythmic auditory cueing versus ASAC used during a walking training in Parkinson's disease.</div></div><div><h3>Methods</h3><div><span><span>Fifteen patients with Parkinson's disease performed both interventions in randomized order, one week apart: a 20-minute walking training with rhythmic auditory cueing, in form of a metronome adjusted on 110% of the patient's own cadence, or ASAC delivered when the stride length is less than 110% of the patient's own stride length. Assessment criteria were walking distance covered during the intervention, speed, </span>step length, cadence, coefficients of variation of step length and step duration, and indexes of spatial and temporal asymmetry during a </span>walking test before and just after the intervention.</div></div><div><h3>Results</h3><div>The walking distance is higher with ASAC compared with rhythmic auditory cueing (rhythmic auditory cueing, 905 (203) m, mean (standard deviation); ASAC, 1043 (212) m; <em>P</em> <!-->=<!--> <!-->0.002). Between-intervention comparison showed some similar effects on walking after the intervention including free speed and step length increases (<em>P</em> <!-->&lt;<!--> <!-->0.05).</div></div><div><h3>Conclusion</h3><div>The distance covered during 20-minute walking with ASAC increases by 15% compared to the use of classical rhythmic auditory cueing, while the immediate therapeutic effects show similar spatial-temporal benefits on short-distance walking. Auditory biofeedback cueing promoting the increase in step length might improve gait relearning in Parkinson's disease.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"180 8","pages":"Pages 798-806"},"PeriodicalIF":2.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revue neurologique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1